Breaking News
December 12, 2017 - CAR T cell therapy shows long-lasting remissions in non-Hodgkin’s lymphoma patients
December 12, 2017 - Live-cell microscopy reveals internal forces that direct cell migration
December 12, 2017 - GSK Submits US Regulatory Application for Single-Dose Tafenoquine for Plasmodium vivax Malaria
December 12, 2017 - High Blood Urea Nitrogen Levels Tied to T2D Risk
December 12, 2017 - Blood Smear: MedlinePlus Lab Test Information
December 12, 2017 - Atopic eczema—one size does not fit all
December 12, 2017 - Biological Applications of AFM
December 12, 2017 - Study provides new insights into mechanism of tumor survival in glioblastoma
December 12, 2017 - FDA Approves Admelog (insulin lispro) Short-Acting “Follow-On” Insulin Product to Treat Diabetes
December 12, 2017 - Chromosomes Fact Sheet – National Human Genome Research Institute (NHGRI)
December 12, 2017 - Discovery puts the brakes on HIV’s ability to infect
December 12, 2017 - Researchers uncover novel strategy to program immune system for fighting cancer
December 12, 2017 - Study finds under-age marriage for women as marker of multiple vulnerabilities
December 12, 2017 - Scientists discover specific mechanism of Zika virus-associated microcephaly
December 12, 2017 - Creating Your Family Health Tree
December 12, 2017 - Biological Pathways Fact Sheet – National Human Genome Research Institute (NHGRI)
December 12, 2017 - LSUHealthNO breakthrough may pave way for advances in obesity-related diseases
December 12, 2017 - Few people with HIV get prompt care after incarceration
December 11, 2017 - Air pollution exposure before or after conception linked to increased risk of birth defects in children
December 11, 2017 - Abu Dhabi focuses on reducing childhood obesity
December 11, 2017 - Employees with influenza have more lost work time
December 11, 2017 - type 2 diabetes – Genetics Home Reference
December 11, 2017 - Insufficient evidence to guide recommendations on vitamin D in pregnancy
December 11, 2017 - St. Jude gene therapy offers hope for infants with ‘bubble boy’ disease
December 11, 2017 - Soy foods, cruciferous vegetables may reduce breast cancer treatment’s side effects
December 11, 2017 - Nearly 3 in 10 elite footballers at top clubs have undetected lung and airway problems, study finds
December 11, 2017 - Why some workers can’t call it quits
December 11, 2017 - Healthier Diet, Less Salt: The Recipe to Beat High Blood Pressure: MedlinePlus Health News
December 11, 2017 - Research leads to call for lung health screening at top football clubs
December 11, 2017 - Drug improves disease-free, overall survival after hematopoietic stem cell transplants
December 11, 2017 - Researchers generate 3D cell cultures to investigate mechanisms of drug resistance in breast cancer
December 11, 2017 - New, more easily administered therapies offer benefits for bleeding and clotting disorders
December 11, 2017 - Opioids after surgery left her addicted. Is that a medical error?
December 11, 2017 - Scientists develop software that predicts leukemia-specific immune targets
December 11, 2017 - Does Your Pet Have a Weight Problem? Here’s How to Tell: MedlinePlus Health News
December 11, 2017 - Genetic variant prompts cells to store fat, fueling obesity
December 11, 2017 - Canola oil linked to worsening of Alzheimer’s
December 11, 2017 - New Breast Cancer Drug Ribociclib (Kisqali) May Benefit Younger Women, Too
December 11, 2017 - Healthy Living May Ease Some MS Symptoms: MedlinePlus Health News
December 11, 2017 - Researchers develop a molecular taxonomy for hair disorders
December 11, 2017 - Study shows safety, efficacy of cystic fibrosis drug in children between 1 to 2 years of age
December 11, 2017 - Two immunotherapy approaches for multiple myeloma show hope
December 11, 2017 - The Valley Hospital uses novel mobile app to enhance pre-hospital emergency care
December 11, 2017 - ‘I Entered Medical School Through a Hunger Strike’: What We Heard This Week
December 11, 2017 - Research team unlocks secrets of Ebola
December 11, 2017 - Generic versions of Viagra coming this week
December 11, 2017 - New genetic model identified for predicting outcomes in patients with primary myelofibrosis
December 11, 2017 - Research shows that e-cigarettes serve as gateway to traditional smoking
December 11, 2017 - A risk factor for drug-induced skin disease identified
December 11, 2017 - MIT researchers discover new way to make bacteria vulnerable to existing antibiotics
December 11, 2017 - Dengue vaccine issues in the Philippines
December 11, 2017 - Office Workers Don’t Like Being Chained to Their Desks: MedlinePlus Health News
December 11, 2017 - Study reveals how a very low calorie diet can reverse type 2 diabetes
December 11, 2017 - Study highlights potential for reducing greenhouse gas emissions in health care settings
December 11, 2017 - University of Adelaide receives $23.2 million for preterm birth research
December 11, 2017 - Tough Flu Season Ahead: Vaccine May Only Be 10% Effective
December 11, 2017 - Getting Self-Driving Cars on the Road Soon Might Save Lives: MedlinePlus Health News
December 11, 2017 - Enterovirus vaccine prevents virus-induced diabetes in a T1D experimental model
December 11, 2017 - Solar retinopathy or sun damage to the eyes – a case report
December 11, 2017 - Cancer risk with birth control pills emerges again in latest study
December 10, 2017 - Deer Hunters: Put Safety First: MedlinePlus Health News
December 10, 2017 - High blood pressure is redefined as 130, not 140: US guidelines (Update)
December 10, 2017 - Unusual neuroinflammation may underlie cognitive problems in cART-treated HIV patients
December 10, 2017 - Racial differences in parents’ reports of child’s autism symptoms may contribute to delayed diagnosis
December 10, 2017 - Taurine could boost effectiveness of existing multiple sclerosis therapies
December 10, 2017 - The man with a young woman’s heart
December 10, 2017 - Patient bedside remains important component of medical education for students
December 10, 2017 - Nutrition labeling has little impact on sodium consumption
December 10, 2017 - ‘Obesity paradox’ not present among people with new cases of cardiovascular disease
December 10, 2017 - SLU scientists provide promising approach in designing new drugs for DMD
December 10, 2017 - Can PD-1 Inhibitor Help Eradicate HIV?
December 10, 2017 - Checking Prices for Medical Procedures Online? Good Luck: MedlinePlus Health News
December 10, 2017 - Researchers find bacteria tied to esophageal cancer
December 10, 2017 - Boy’s Double Hand Transplant Changed His Brain
December 10, 2017 - Memo to Doctors: Spit Out the Bad News: MedlinePlus Health News
December 10, 2017 - Two years of extended anastrozole therapy proved as effective as five years in clinical trial
December 10, 2017 - Using digital devices before bed may contribute to sleep and nutrition problems in children
December 10, 2017 - Are You Sure That’s What the Doctor Said About Your Leukemia?: MedlinePlus Health News
December 10, 2017 - Low vitamin D levels at birth linked to higher autism risk
December 10, 2017 - Alcohol use in movies influences onset of drinking among 10- to 15-year-olds
New small-molecule drug restores brain function, memory in mouse model of Alzheimer’s disease

New small-molecule drug restores brain function, memory in mouse model of Alzheimer’s disease

image_pdfDownload PDFimage_print

An international team of researchers has shown that a new small-molecule drug can restore brain function and memory in a mouse model of Alzheimer’s disease. The drug works by stopping toxic ion flow in the brain that is known to trigger nerve cell death. Scientists envision that this drug could be used to treat Alzheimer’s and other neurodegenerative diseases such as Parkinson’s and ALS.

“This is the first drug molecule that can regulate memory loss by directly blocking ions from leaking through nerve cell membranes,” said Ratnesh Lal, a professor of bioengineering at the University of California San Diego and co-senior author of the study.

Various studies have linked Alzheimer’s disease to the accumulation of two particular proteins in the brain called amyloid-beta and tau. One theory is that these protein clusters create pores in nerve cell membranes that allow ions to travel in and out uncontrollably. This would alter ion levels inside the cells and in turn trigger neuronal dysfunction and cell death.

The new drug, a small molecule called anle138b, blocks these pores from moving ions in and out of nerve cells. Anle138b attaches to both amyloid-beta and tau protein clusters and deactivates the pores created by these clusters.

Researchers administered anle138b to mice with a genetic predisposition for developing an Alzheimer’s-like condition. The mice had symptoms such as abnormal brain function, impaired memory and high levels of either amyloid-beta or tau proteins in the brain. Treatment with anle138b normalized brain activity and improved learning ability in mice.

The study was led by the German Center for Neurodegenerative Diseases, the University Medical Center Göttingen, the Braunschweig University of Technology, the Max Planck Institute for Biophysical Chemistry, the Center for Nanoscale Microscopy and Molecular Physiology of the Brain in Göttingen, Germany, and the University of California San Diego. Researchers published their findings on Dec. 5 in EMBO Molecular Medicine.

Christian Griesinger, a professor at the Max Planck Institute for Biophysical Chemistry and co-senior author of the study, noted, “The drug is able to reach the brain when taken orally. Therefore, it is easy to administer, and we are currently performing toxicology studies to eventually be able to apply anle138b to humans.”

The team cautions that since the drug has so far only been tested in mice, it is unclear how well it would perform in humans. “I would like to emphasize that none of the current animal models fully recapitulate the symptoms seen in Alzheimer’s patients. Thus, care has to be taken when interpreting such data. However, our study offers evidence that anle138b has potential for neuroprotection,” said André Fischer, a senior researcher at the German Center for Neurodegenerative Diseases and the University Medical Center Göttingen, who is also a co-senior author of the study.

While collaborators in Germany will be pursuing clinical studies in human patients with neurodegenerative diseases, Lal and his research group at the UC San Diego Jacobs School of Engineering are particularly interested in testing anle138b on a variety of other diseases that are linked to toxic ion flow caused by amyloid proteins, including diabetes, tuberculosis and certain types of cancer. Lal’s group has performed extensive research on amyloid ion channels and their roles in these diseases. “Blocking the ion leakiness of amyloid channels using anle138b could be an effective therapy for various diseases,” Lal said.

Lal serves as co-director for the Center of Excellence for Nanomedicine and Engineering, a subcenter of the Institute of Engineering in Medicine at UC San Diego. His research group will also work on targeted delivery of the drug using their patent pending “nanobowls,” which are magnetically guided nanoparticles that can be packed with drugs and diagnostic molecules, deliver them to particular sites in the body and release them on demand. Future studies will focus on using these nanobowls to deliver anle138b to the brain, as well as other diseased tissues and organs affected by toxic amyloid-beta ion channels.

Source:

http://ucsdnews.ucsd.edu/pressrelease/experimental_drug_block_toxic_ion_flow_linked_to_alzheimers_disease

Tagged with:

About author

Related Articles